International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(4), P. 2255 - 2255
Published: Feb. 18, 2022
Schistosomiasis,
caused
by
human
trematode
blood
flukes
(schistosomes),
remains
one
of
the
most
prevalent
and
serious
neglected
tropical
parasitic
diseases.
Currently,
treatment
schistosomiasis
relies
solely
on
a
single
drug,
anthelmintic
praziquantel,
with
increased
usage
in
mass
drug
administration
control
programs
for
disease,
specter
resistance
developing
is
constant
threat.
Vaccination
recognized
as
sustainable
options
any
pathogen,
but
despite
discovery
reporting
numerous
potentially
promising
schistosome
vaccine
antigens,
to
date,
no
or
animal
deployment
available.
This
fact
that
Science
ranked
such
an
intervention
top
10
vaccines
need
be
urgently
developed
improve
public
health
globally.
review
summarizes
current
progress
under
clinical
development
advocates
urgent
establishment
revolutionary
effective
anti-schistosome
pipeline
utilizing
cutting-edge
technologies
(including
mRNA
exploiting
CRISPR-based
technologies)
provide
novel
insight
into
future
discovery,
design,
manufacture
deployment.
Advanced Healthcare Materials,
Journal Year:
2021,
Volume and Issue:
10(8)
Published: Jan. 18, 2021
Abstract
Nucleic
acid
vaccines
are
a
method
of
immunization
aiming
to
elicit
immune
responses
akin
live
attenuated
vaccines.
In
this
method,
DNA
or
messenger
RNA
(mRNA)
sequences
delivered
the
body
generate
proteins,
which
mimic
disease
antigens
stimulate
response.
Advantages
nucleic
include
stimulation
both
cell‐mediated
and
humoral
immunity,
ease
design,
rapid
adaptability
changing
pathogen
strains,
customizable
multiantigen
To
combat
SARS‐CoV‐2
pandemic,
many
other
diseases,
appear
be
promising
method.
However,
aid
is
needed
in
delivering
fragile
DNA/mRNA
payload.
Many
delivery
strategies
have
been
developed
effective
stimulation,
yet
no
vaccine
has
FDA‐approved
for
human
use.
Nanoparticles
(NPs)
one
top
candidates
mediate
successful
due
their
unique
properties,
including
unlimited
possibilities
formulations,
protective
capacity,
simultaneous
loading,
potential
multiple
This
review
will
summarize
varieties
novel
NP
formulations
mRNA
as
well
give
reader
brief
synopsis
clinical
trials.
Finally,
future
perspectives
challenges
NP‐mediated
explored.
Molecular Therapy,
Journal Year:
2021,
Volume and Issue:
29(6), P. 1970 - 1983
Published: April 5, 2021
A
self-transcribing
and
replicating
RNA
(STARR)-based
vaccine
(LUNAR-COV19)
has
been
developed
to
prevent
SARS-CoV-2
infection.
The
encodes
an
alphavirus-based
replicon
the
full-length
spike
glycoprotein.
Translation
of
produces
a
replicase
complex
that
amplifies
prolongs
glycoprotein
expression.
single
prime
vaccination
in
mice
led
robust
antibody
responses,
with
neutralizing
titers
increasing
up
day
60.
Activation
cell-mediated
immunity
produced
strong
viral
antigen-specific
CD8+
T
lymphocyte
response.
Assaying
for
intracellular
cytokine
staining
interferon
(IFN)γ
interleukin-4
(IL-4)-positive
CD4+
helper
(Th)
lymphocytes
as
well
anti-spike
immunoglobulin
G
(IgG)2a/IgG1
ratios
supported
Th1-dominant
immune
Finally,
LUNAR-COV19
at
both
2
μg
10
doses
completely
protected
human
ACE2
transgenic
from
mortality
even
measurable
infection
following
wild-type
challenge.
Our
findings
collectively
suggest
potential
single-dose
vaccine.
Acta Pharmaceutica Sinica B,
Journal Year:
2022,
Volume and Issue:
12(7), P. 2969 - 2989
Published: March 24, 2022
Patients
exhibit
good
tolerance
to
messenger
ribonucleic
acid
(mRNA)
vaccines,
and
the
choice
of
encoded
molecules
is
flexible
diverse.
These
vaccines
can
be
engineered
express
full-length
antigens
containing
multiple
epitopes
without
major
histocompatibility
complex
(MHC)
restriction,
are
relatively
easy
control
rapidly
mass
produced.
In
2021,
U.S.
Food
Drug
Administration
(FDA)
approved
first
mRNA-based
coronavirus
disease
2019
(COVID-19)
vaccine
produced
by
Pfizer
BioNTech,
which
has
generated
enthusiasm
for
mRNA
research
development.
Based
on
above
characteristics
development
cancer
have
become
a
hotspot
undergone
rapid
development,
especially
in
last
five
years.
This
review
analyzes
advances
from
various
perspectives,
including
selection
expression
antigens/targets,
application
vectors
adjuvants,
different
administration
routes,
preclinical
evaluation,
reflect
trends
challenges
associated
with
these
vaccines.
Small,
Journal Year:
2023,
Volume and Issue:
19(36)
Published: April 29, 2023
Abstract
The
protein
corona
forms
spontaneously
on
nanoparticle
surfaces
when
nanomaterials
are
introduced
into
any
biological
system/fluid.
Reliable
characterization
of
the
is,
therefore,
a
vital
step
in
development
safe
and
efficient
diagnostic
therapeutic
nanomedicine
products.
2134
published
manuscripts
reviewed
down‐selection
470
papers
spanning
2000–2021,
comprising
1702
(NP)
systems
is
analyzed.
This
analysis
reveals:
i)
most
studies
have
been
conducted
metal
oxide
nanoparticles;
ii)
despite
their
overwhelming
presence
clinical
practice,
lipid‐based
NPs
underrepresented
research,
iii)
use
new
methods
to
improve
reliability
reproducibility
research;
iv)
more
specific
sources
toward
personalized
medicine;
v)
careful
nanoparticles
after
formation
imperative
minimize
role
aggregation
contamination
outcomes.
As
used
biomedicine
become
increasingly
prevalent
biochemically
complex,
field
research
will
need
focus
developing
analytical
approaches
techniques
appropriate
for
each
unique
formulation.
Achieving
such
nano‐bio
interface
nanobiotechnologies
enable
seamless
implementation
medicine.
Exploration,
Journal Year:
2023,
Volume and Issue:
4(2)
Published: Nov. 17, 2023
Abstract
mRNA
therapeutics
have
emerged
as
powerful
tools
for
cancer
immunotherapy
in
accordance
with
their
superiority
expressing
all
sequence‐known
proteins
vivo.
In
particular,
a
small
dosage
of
delivered
mRNA,
antigen‐presenting
cells
(APCs)
can
synthesize
mutant
neo‐antigens
and
multi‐antigens
present
epitopes
to
T
lymphocytes
elicit
antitumor
effects.
addition,
receptors
like
chimeric
antigen
receptor
(CAR),
T‐cell
(TCR),
CD134,
immune‐modulating
factors
including
cytokines,
interferons,
antibodies
specific
enhance
immunological
response
against
tumors.
With
the
maturation
vitro
transcription
(IVT)
technology,
large‐scale
pure
encoding
be
synthesized
quickly.
However,
clinical
translation
mRNA‐based
anticancer
strategies
is
restricted
by
delivering
into
target
organs
or
inadequate
endosomal
escape
efficiency
mRNA.
Recently,
there
been
some
advances
immunotherapy,
which
roughly
classified
modifications
structure
development
delivery
systems,
especially
lipid
nanoparticle
platforms.
this
review,
latest
overcoming
limitations
immunotherapies
recent
are
summarized.
Challenges
opportunities
applications
also
discussed.
Experimental Hematology and Oncology,
Journal Year:
2025,
Volume and Issue:
14(1)
Published: Jan. 31, 2025
Liposomes
and
lipid
nanoparticles
are
common
lipid-based
drug
delivery
systems
play
important
roles
in
cancer
treatment
vaccine
manufacture.
Although
significant
progress
has
been
made
with
these
nanocarriers
recent
years,
efficient
clinical
translation
of
active
targeted
liposomal
remains
extremely
challenging.
In
this
review,
we
focus
on
liposomes,
stimuli-responsive
strategy
combined
therapy
treatment.
We
also
summarize
advances
liposome
nanoparticle
applications
nucleic
acid
tumor
vaccination.
addition,
discuss
limitations
challenges
the
nanomaterials
make
recommendations
for
future
research
therapy.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2025,
Volume and Issue:
13
Published: March 12, 2025
The
advent
of
mRNA
vaccines,
accelerated
by
the
global
response
to
COVID-19
pandemic,
marks
a
transformative
shift
in
vaccine
technology.
In
this
article,
we
discuss
development,
current
applications,
and
prospects
vaccines
for
both
prevention
treatment
infectious
diseases
oncology.
By
leveraging
capacity
encode
antigens
within
host
cells
directly,
provide
versatile
scalable
platform
suitable
addressing
broad
spectrum
pathogens
tumor-specific
antigens.
We
highlight
recent
advancements
design,
innovative
delivery
mechanisms,
ongoing
clinical
trials,
with
particular
emphasis
on
their
efficacy
combating
diseases,
such
as
COVID-19,
Zika,
influenza,
well
emerging
potential
cancer
immunotherapy.
also
address
critical
challenges,
including
stability,
optimization
immune
responses,
broader
issue
accessibility.
Finally,
review
strategies
advancing
next-generation
aim
overcoming
limitations
technology
enhancing
preventive
therapeutic
approaches
oncological
diseases.
